Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM38ARE)

Drug Name

Gp100:209-217(210M) peptide vaccine Drug Info

Synonyms

Gp100 melanoma-associated antigen vaccine, NCI; Gp100:209-217(210M) peptide vaccine (melanoma); Gp100:209-217(210M) peptide vaccine (melanoma), NCI

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanocytes lineage-specific antigen GP100 (PMEL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[3]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[4]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[5]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[6]
AE-08	DM7X2HK	Melanoma	2C30	Phase 1	[7]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocytes lineage-specific antigen GP100 (PMEL)	TT8MK59	PMEL_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00003895) Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma. U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug id 476335).
3	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
4	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
5	National Cancer Institute Drug Dictionary (drug id 685201).
6	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
7	Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
8	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.